Prostate cancer real-world evidence registry
Part of Cancer, Kidney & urinary clinical trials.
This study collects information from men with prostate cancer to better understand how different treatments work in real life. It follows patients when they start a new treatment and can help improve future care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older with prostate cancer.
- You are starting a new treatment for your cancer (or started one within the past 4 weeks).
- Your cancer falls into one of four groups: rising PSA after local treatment, or non-spreading but treatment-resistant, or spreading but hormone-sensitive, or spreading and treatment-resistant.
- For some groups, your cancer must not be able to be treated with local therapy (or you choose not to have it).
- You must be able and willing to sign a consent form to participate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is a worldwide registry that collects health information from men with advanced prostate cancer. It may help researchers better understand disease patterns and outcomes, which can guide future treatments.
This study builds a database of people with localized or locally advanced prostate cancer to better understand patient-reported outcomes (your experiences and quality-of-life). It may help improve future care by collecting consistent feedback from patients.
This registry collects information from people with prostate cancer to better understand how genetics and treatments affect survival and outcomes. Your data may help researchers improve future treatment choices.
This is a registry study that follows men with low-risk prostate cancer who choose active surveillance instead of immediate treatment. It helps doctors understand how safe and effective active surveillance is, including confirming results with repeat biopsies.
This study looks at how social, lifestyle, and other factors affect prostate cancer outcomes. It enrolls men who have chosen to have their prostate removed (radical prostatectomy) and agreed to join a biobank.
This study tests if a smartphone-based tracking system can help doctors decide when to change treatment for men with hormone-sensitive prostate cancer that has spread. It uses standard drugs (relugolix and an ARPI) and monitors PSA levels closely.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.